GlassScriptPhysician profile
Ramani Peruvemba
NPI 1619924701
$6,652.15
in general payments reported to CMS, 2019-2025
25 companies · $1,623 in 2025
The $1,623 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.00 · 2020: $565 · 2021: $147 · 2022: $2,237 · 2023: $1,129 · 2024: $875 · 2025: $1,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,866 · Travel and Lodging: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,865.76 |
| Travel and Lodging | $760.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mml US, INC. | $2,299.42 | 2022-2024 | Reactiv8 |
| Pacira Pharmaceuticals Incorporated | $964.32 | 2025 | Iovera |
| Medtronic, INC. | $847.09 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Abbott Laboratories | $568.81 | 2020-2024 | Proclaim, Eterna |
| Globus Medical, INC. | $269.07 | 2025 | Senza |
| Boston Scientific Corporation | $222.21 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Medtronic USA, INC. | $198.22 | 2019-2020 | |
| Nevro Corp. | $173.76 | 2021-2023 | Senza |
| Curonix LLC | $137.25 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Merck Sharp & Dohme LLC | $119.81 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $102.77 | 2023-2025 | Xtampza, Belbuca |
| Tersera Therapeutics LLC | $97.70 | 2023-2025 | Prialt |
| Spr Therapeutics, INC | $94.48 | 2023 | Sprint Pns System |
| Axogen | $90.55 | 2025 | |
| Vertos Medical, INC. | $80.68 | 2023-2024 | Mild Device Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $72.90 | 2022-2023 | Intracept |
| Fidia Pharma USA INC. | $50.75 | 2019-2023 | Triluron, Hymovis |
| Abbvie INC. | $48.93 | 2024 | |
| Stryker Corporation | $48.05 | 2023 | Multigen 2 |
| Avanos Medical | $47.53 | 2021 | |
| Saluda Medical Americas, INC. | $47.41 | 2024 | Evoke |
| Heron Therapeutics, INC. | $24.11 | 2021 | |
| Painteq LLC | $22.27 | 2024 | Painteq |
| Ambu INC. | $17.45 | 2022 | |
| Foundation Fusion Solutions, LLC | $6.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramani Peruvemba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.